HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $30 Price Target
First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics Inc TRAX | 0.00 |
HC Wainwright & Co. analyst Emily Bodnar reiterates First Tracks (NASDAQ:
TRAX) with a Buy and maintains $30 price target.
